205 related articles for article (PubMed ID: 9685694)
1. Transgenic assays for mutations and cancer: current status and future perspectives.
Vijg J; van Steeg H
Mutat Res; 1998 May; 400(1-2):337-54. PubMed ID: 9685694
[TBL] [Abstract][Full Text] [Related]
2. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays.
Benigni R; Bossa C; Tcheremenskaia O; Giuliani A
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):809-19. PubMed ID: 20438313
[TBL] [Abstract][Full Text] [Related]
3. Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals--scientific perspective.
Storer RD
Toxicol Lett; 2000 Mar; 112-113():557-66. PubMed ID: 10720780
[TBL] [Abstract][Full Text] [Related]
4. Expectations for transgenic rodent cancer bioassay models.
Ashby J
Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
[TBL] [Abstract][Full Text] [Related]
5. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
Ward JM
Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
[TBL] [Abstract][Full Text] [Related]
6. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
7. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Forum Opinion Piece: Carcinogen Risk Assessment: The Move from Screens to Science.
Downes N; Foster J
Toxicol Pathol; 2015 Dec; 43(8):1064-73. PubMed ID: 26296629
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Emu-pim-1 transgenic mouse model for short-term carcinogenicity testing.
van Kreijl CF; van der Houven van Oordt CW; Kroese ED; Sørensen IK; Breuer ML; Storer RD
Toxicol Pathol; 1998; 26(6):750-6. PubMed ID: 9864091
[TBL] [Abstract][Full Text] [Related]
10. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
11. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
12. Panel discussion on the application of alternative models to cancer risk assessment.
Pettit SD
Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
[TBL] [Abstract][Full Text] [Related]
13. Use of transgenic animals in carcinogenesis studies.
Gonzalez FJ
Mol Carcinog; 1996 Jun; 16(2):63-7. PubMed ID: 8645427
[No Abstract] [Full Text] [Related]
14. Use of transgenic mice in carcinogenicity hazard assessment.
Jacobson-Kram D; Sistare FD; Jacobs AC
Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
[TBL] [Abstract][Full Text] [Related]
15. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
Battershill JM; Fielder RJ
Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
[TBL] [Abstract][Full Text] [Related]
16. The use of biotechnical recombinant-mice to test the safety of potential carcinogenic pharmaceuticals.
Inoue T
J Toxicol Sci; 1995 Sep; 20(4):468-70. PubMed ID: 8531244
[No Abstract] [Full Text] [Related]
17. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors.
Cohen SM
Asian Pac J Cancer Prev; 2010; 11(1):15-7. PubMed ID: 20593920
[TBL] [Abstract][Full Text] [Related]
18. Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals.
Shirai T; Hirose M; Ito N
IARC Sci Publ; 1999; (146):251-72. PubMed ID: 10353390
[No Abstract] [Full Text] [Related]
19. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing.
van Steeg H; Klein H; Beems RB; van Kreijl CF
Toxicol Pathol; 1998; 26(6):742-9. PubMed ID: 9864090
[TBL] [Abstract][Full Text] [Related]
20. In vitro carcinogenicity testing: present and future perspectives in pharmaceutical development.
Kowalski LA
Curr Opin Drug Discov Devel; 2001 Jan; 4(1):29-35. PubMed ID: 11727320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
